Primevera Therapeutics News

Foresee Licenses MMP‑12 Inhibitors to Primevera for $594m

January 8, 2026

Foresee Pharmaceuticals grants Primevera exclusive global rights to MMP‑12 inhibitors FP‑025, FP‑020 and discovery assets for $10m upfront, up to $584.5m milestones, royalties and 19% equity.